Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Fierce Pharma
Novo reports 2 trial failures for GLP-1 in Alzheimer's disease
Novo's share price dropped in reaction to the company coming up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease.
Kevin Dunleavy
Nov 24, 2025 11:41am
Ventyx's CV drug rapidly reduces cardio risk biomarker
Oct 23, 2025 9:45am
Skye's CB1 blocker fails to reduce weight in obesity study
Oct 6, 2025 7:55am
Pfizer’s new prize Metsera touts 14% weight loss for GLP-1
Sep 30, 2025 6:40am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
Jun 23, 2025 2:30pm
